BR112023024627A2 - Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas - Google Patents
Proteínas renais de fusão ativas e métodos de tratamento usando as mesmasInfo
- Publication number
- BR112023024627A2 BR112023024627A2 BR112023024627A BR112023024627A BR112023024627A2 BR 112023024627 A2 BR112023024627 A2 BR 112023024627A2 BR 112023024627 A BR112023024627 A BR 112023024627A BR 112023024627 A BR112023024627 A BR 112023024627A BR 112023024627 A2 BR112023024627 A2 BR 112023024627A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- treatment methods
- domains
- active kidney
- factor
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 208000007522 Fused Kidney Diseases 0.000 title abstract 2
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 abstract 1
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 108020001778 catalytic domains Proteins 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
Abstract
proteínas renais de fusão ativas e métodos de tratamento usando as mesmas. são aqui descritas proteínas de fusão que incluem domínios catalíticos do fator h e podem incluir domínios vhh, domínios de proteína 5 relacionados ao fator h ou domínios de ligação à integrina, e o uso de tais proteínas de fusão em métodos de tratamento de doenças mediadas pela ativação ou desregulação da via alternativa do complemento, por exemplo, doenças renais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192835P | 2021-05-25 | 2021-05-25 | |
| PCT/US2022/030658 WO2022251168A1 (en) | 2021-05-25 | 2022-05-24 | Kidney active fusion proteins and methods of treatment using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024627A2 true BR112023024627A2 (pt) | 2024-02-20 |
Family
ID=84178944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024627A BR112023024627A2 (pt) | 2021-05-25 | 2022-05-24 | Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4347666A1 (pt) |
| JP (1) | JP2024520421A (pt) |
| KR (1) | KR20240013770A (pt) |
| CN (1) | CN117396519A (pt) |
| AU (1) | AU2022283254A1 (pt) |
| BR (1) | BR112023024627A2 (pt) |
| CA (1) | CA3177162A1 (pt) |
| IL (1) | IL308754A (pt) |
-
2022
- 2022-05-24 CN CN202280035932.2A patent/CN117396519A/zh active Pending
- 2022-05-24 IL IL308754A patent/IL308754A/en unknown
- 2022-05-24 CA CA3177162A patent/CA3177162A1/en active Pending
- 2022-05-24 JP JP2023572788A patent/JP2024520421A/ja active Pending
- 2022-05-24 BR BR112023024627A patent/BR112023024627A2/pt unknown
- 2022-05-24 KR KR1020237044189A patent/KR20240013770A/ko unknown
- 2022-05-24 AU AU2022283254A patent/AU2022283254A1/en active Pending
- 2022-05-24 EP EP22811954.1A patent/EP4347666A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347666A1 (en) | 2024-04-10 |
| CA3177162A1 (en) | 2022-11-25 |
| AU2022283254A1 (en) | 2023-11-30 |
| KR20240013770A (ko) | 2024-01-30 |
| AU2022283254A9 (en) | 2023-12-07 |
| JP2024520421A (ja) | 2024-05-24 |
| IL308754A (en) | 2024-01-01 |
| CN117396519A (zh) | 2024-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60135498D1 (de) | Produktion von ganzen Antikörpern in prokaryontischen Zellen | |
| ATE398676T2 (de) | Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins | |
| ATE251942T1 (de) | Stapelbare statische mischelemente | |
| ATE476654T1 (de) | Plattform für protein-profiling | |
| BRPI0410876A (pt) | molécula inibidora do complemento, anticorpo, proteìna de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteìna de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um aninal desenvolva uma doença ou um disturbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteìna de fusão ou uma molécula de ácido nucleico | |
| UY28170A1 (es) | Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes. | |
| Lai et al. | Matriptase complexes and prostasin complexes with HAI-1 and HAI-2 in human milk: significant proteolysis in lactation | |
| SE8902532L (sv) | Bestaemning av plasmaproteiner | |
| BRPI0414215A (pt) | tienopirazóis | |
| DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
| WO1999049038A3 (en) | Human calcium-binding proteins | |
| ATE384263T1 (de) | Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen | |
| BR112023024627A2 (pt) | Proteínas renais de fusão ativas e métodos de tratamento usando as mesmas | |
| BR0113099A (pt) | Gene e proteìna relacionados com esquizofrenia | |
| DE69913325D1 (de) | Nephrin gen und protein | |
| ATE368687T1 (de) | Thrombopoietinproteine mit verbesserten eigenschaften | |
| DE60332481D1 (de) | Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems | |
| ATE349702T1 (de) | Nachweis und quantifizierung von cripto-1 | |
| CO2023015999A2 (es) | Proteínas de fusión activas renales y métodos de tratamiento que usan las mismas | |
| ATE529536T1 (de) | Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen | |
| ATE545421T1 (de) | Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat | |
| Gilbert et al. | Purification of fibrinogen and virus removal using preparative electrophoresis | |
| DK1377667T3 (da) | Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme | |
| DE60120187D1 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
| ATE193324T1 (de) | Rekombinante herstellung von laktoperoxidase |